Najla Guthrie

Ms. Guthrie joins Ketamine One as part of the previously announced acquisition of KGK Science Inc. from Auxly Cannabis Group Inc., where she has held the role of President & CEO since 1997. Over 23 years, Ms. Guthrie has grown the London-based business to become a leading North American contract research organization that primarily provides high-quality clinical research trials with a focus on the nutraceutical, cannabis and emerging psychedelic industries. Ms. Guthrie has published over 50 papers in peer-reviewed journals and has given numerous presentations at both the national and international levels.